These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16750364)

  • 1. The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist.
    Huck BR; Llamas L; Robarge MJ; Dent TC; Song J; Hodnick WF; Crumrine C; Stricker-Krongrad A; Harrington J; Brunden KR; Bennani YL
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4130-4. PubMed ID: 16750364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
    Liu KK; Cornelius P; Patterson TA; Zeng Y; Santucci S; Tomlinson E; Gibbons C; Maurer TS; Marala R; Brown J; Kong JX; Lee E; Werner W; Wenzel Z; Vage C
    Bioorg Med Chem Lett; 2010 Jan; 20(1):266-71. PubMed ID: 19914063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor.
    Sabb AL; Vogel RL; Welmaker GS; Sabalski JE; Coupet J; Dunlop J; Rosenzweig-Lipson S; Harrison B
    Bioorg Med Chem Lett; 2004 May; 14(10):2603-7. PubMed ID: 15109661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
    Allerton CM; Andrews MD; Blagg J; Ellis D; Evrard E; Green MP; Liu KK; McMurray G; Ralph M; Sanderson V; Ward R; Watson L
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5791-5. PubMed ID: 19716297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
    Shimada I; Maeno K; Kazuta K; Kubota H; Kimizuka T; Kimura Y; Hatanaka K; Naitou Y; Wanibuchi F; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Feb; 16(4):1966-82. PubMed ID: 18035544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists.
    Andrews MD; Green MP; Allerton CM; Batchelor DV; Blagg J; Brown AD; Gordon DW; McMurray G; Millns DJ; Nichols CL; Watson L
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5346-50. PubMed ID: 19692241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.
    Brennan PE; Whitlock GA; Ho DK; Conlon K; McMurray G
    Bioorg Med Chem Lett; 2009 Sep; 19(17):4999-5003. PubMed ID: 19646865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
    Wacker DA; Miller KJ
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.
    Röver S; Adams DR; Bénardeau A; Bentley JM; Bickerdike MJ; Bourson A; Cliffe IA; Coassolo P; Davidson JE; Dourish CT; Hebeisen P; Kennett GA; Knight AR; Malcolm CS; Mattei P; Misra A; Mizrahi J; Muller M; Porter RH; Richter H; Taylor S; Vickers SP
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3604-8. PubMed ID: 15975787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
    Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Dosa PI; Covel JA; Ren A; Webb RR; Beeley NR; Martin M; Morgan M; Espitia S; Saldana HR; Bjenning C; Whelan KT; Grottick AJ; Menzaghi F; Thomsen WJ
    J Med Chem; 2008 Jan; 51(2):305-13. PubMed ID: 18095642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
    Ahmad S; Ngu K; Miller KJ; Wu G; Hung CP; Malmstrom S; Zhang G; O'Tanyi E; Keim WJ; Cullen MJ; Rohrbach KW; Thomas M; Ung T; Qu Q; Gan J; Narayanan R; Pelleymounter MA; Robl JA
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1128-33. PubMed ID: 20022752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.
    Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Thomsen WJ; Saldana HR; Whelan KT; Menzaghi F; Webb RR; Beeley NR
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1467-70. PubMed ID: 15713408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT2C receptor agonists with potential anorectic activity.
    Yoon G; Jeong HJ; Kim JJ; Cheon SH
    Arch Pharm Res; 2008 Aug; 31(8):989-94. PubMed ID: 18787786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
    Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
    Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
    Shimada I; Maeno K; Kondoh Y; Kaku H; Sugasawa K; Kimura Y; Hatanaka K; Naitou Y; Wanibuchi F; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Mar; 16(6):3309-20. PubMed ID: 18083579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.
    Hamprecht D; Micheli F; Tedesco G; Donati D; Petrone M; Terreni S; Wood M
    Bioorg Med Chem Lett; 2007 Jan; 17(2):424-7. PubMed ID: 17079142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR of tolylamine 5-HT6 antagonists.
    Singer JM; Wilson MW; Johnson PD; Graham SR; Cooke LW; Roof RL; Boxer PA; Gold LH; Meltzer LT; Janssen A; Roush N; Campbell JE; Su TZ; Hurst SI; Stoner CL; Schwarz JB
    Bioorg Med Chem Lett; 2009 May; 19(9):2409-12. PubMed ID: 19346128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.
    Cole DC; Stock JR; Lennox WJ; Bernotas RC; Ellingboe JW; Boikess S; Coupet J; Smith DL; Leung L; Zhang GM; Feng X; Kelly MF; Galante R; Huang P; Dawson LA; Marquis K; Rosenzweig-Lipson S; Beyer CE; Schechter LE
    J Med Chem; 2007 Nov; 50(23):5535-8. PubMed ID: 17948978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the 5-HT2C receptor in improving weight-supported stepping in adult rats spinalized as neonates.
    Kao T; Shumsky JS; Jacob-Vadakot S; Himes BT; Murray M; Moxon KA
    Brain Res; 2006 Sep; 1112(1):159-68. PubMed ID: 16914121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.